Supplementary Table S2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

André Souza; Matthew J. Hadfield; Shaolei Lu; Dragan J. Golijanin; Roxanne Wood; Jeannine Margolis; Kate Anderson; Adam J. Olszewski; Sheldon L. Holder; Wafik S. El‐Deiry; Rahul Aggarwal; Anthony Mega; Benedito A. Carneiro

doi:10.1158/2767-9764.30849271

Abstract

<p>Supplementary Table S2. Representativeness of Study Participants</p>

Related Publications

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida , Joanna Cyrta , Glenn Heller +40 more

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of...

2019 Proceedings of the National Academy o... 1301 citations

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor , Johann S. de Bono , Kim N. +17 more

BACKGROUND: Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic ca...

2021 New England Journal of Medicine 2181 citations

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono , Joaquı́n Mateo , Karim Fizazi +17 more

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...

2020 New England Journal of Medicine 2067 citations

Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Alan B. Sandler , John Nemunaitis , Claude Denham +10 more

PURPOSE: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable pa...

2000 Journal of Clinical Oncology 716 citations

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. , Neeraj Agarwal , Anders Bjartell +17 more

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer wit...

2019 New England Journal of Medicine 1384 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Supplementary Table S2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

CrossRef

Cite This

APA Style

                            
                                    André Souza, 
                                
                                    Matthew J. Hadfield, 
                                
                                    Shaolei Lu
                                
                                et al.
                            
                            (2025). 
                            Supplementary Table S2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). 
                            
                            .
                            https://doi.org/10.1158/2767-9764.30849271

Identifiers

DOI: 10.1158/2767-9764.30849271

Data Quality

Data completeness: 66%